Trial · NCT06244485
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485, Phase 1, Active not recruiting, Daiichi Sankyo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors. Trials, record NCT06244485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06244485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- NCT number
- NCT06244485
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 210 participants, estimated
- Lead sponsor
- Daiichi Sankyo
- Conditions
- Advanced Solid Tumor
- Interventions
- Valemetostat tosylate, T-DXd, Dato-DXd
- First posted
- 2024-02-06
- Last updated
- 2026-09-15
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Reporting Dose-limiting Toxicities (Part 1 Dose Escalation) | Cycle 1 Day 1 up to Day 21 (each cycle is 21 days) | |
| Primary | Number of Participants Reporting Treatment-emergent Adverse Events (Part 1 Dose Escalation) | Screening up to 40 days after last dose, up to approximately 5 years | |
| Primary | Objective Response Rate Based on Investigator Assessment (Part 2 Dose Expansion) | Baseline (Screening), at every 6 weeks from Cycle 1 Day 1 in the first year, and every 12 weeks thereafter until disease progression or until the start of a new anticancer treatment, up to approximately 5 years | |
| Secondary | Overall Survival | Date of first dose up to date of death due to any cause, up to approximately 5 years | |
| Secondary | Progression-free Survival | Date of first dose up to date of radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 5 years | Progression-free survival will be assessed by RECIST v 1.1 criteria. |
| Secondary | Duration of Response (DoR) | Date of first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of objective tumor progression or to death due to any cause (whichever occurs first), up to approximately 5 years | |
| Secondary | Objective Response Rate Per Investigator Assessment Based on RECIST v1.1 (Part 1 Dose Escalation) | Baseline (Screening), at every 6 weeks from Cycle 1 Day 1 in the first year, and every 12 weeks thereafter until disease progression or until the start of a new anticancer treatment, up to approximately 5 years | |
| Secondary | Number of Participants Reporting Treatment-emergent Adverse Events (Part 2 Dose Expansion) | Screening up to 40 days after last dose, up to approximately 5 years | |
| Secondary | Total and Unbound Plasma Concentration of Valemetostat | Cycle 1, Day 1 up to approximately 5 years (cycle length=21 days) | |
| Secondary | Plasma Concentration of DXd Antibody-Drug Conjugates | Cycle 1, Day 1 up to approximately 5 years (cycle length=21 days) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06244485
GET https://conductscience.org/api/trials/v1/NCT06244485/registered